Mesoblast Limited reported a 44 percent increase in net revenue from Ryoncil to US$28 million in the first fiscal quarter of 2026, compared with US$19 million in the prior year period. More notably, the company achieved an 85 percent improvement in net operating cash spend, which fell to just US$2.3 million from US$14.9 million in the equivalent period, while maintaining a cash position of US$99 million. These metrics suggest the company is moving toward a more sustainable operational model as its commercialization effort matures.
The revenue growth and dramatic reduction in operating cash burn reflect disciplined execution by management. Ryoncil, approved by the FDA for pediatric steroid-refractory acute graft-versus-host disease, began to penetrate its addressable market more effectively in the quarter. September recorded the highest number of new patient starts in a single month, an indicator that adoption is accelerating beyond the expected seasonal softness that occurs during summer months when treatment scheduling typically lags. The company operates across 54 onboarded sites, providing a foundation for further penetration as clinical awareness and adoption grow.
The financial trajectory matters because it demonstrates that the commercialization phase can generate sufficient revenue to support ongoing operations while funding clinical development. For a cell therapy company, this transition from cash-burn to cash-neutral operations is meaningful. Management has signaled an intention to maintain disciplined capital allocation, directing resources toward expansion of manufacturing capacity and late-stage clinical programs. The company is advancing Ryoncil into additional indications including steroid-refractory aGvHD in adults and biologic-resistant inflammatory bowel disease, while rexlemestrocel-L remains in development for heart failure and chronic low back pain.
Mesoblast’s intellectual property portfolio provides durable competitive protection. The company holds over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions, manufacturing methods, and indications, with protection extending through at least 2044 in major markets. This patent estate creates a moat around the core technology platform. Regional partnerships in Japan, Europe, and China signal confidence from potential collaborators in the broader therapeutic potential of the platform beyond the current Ryoncil indication.
Investors should track adoption rates across the 54 sites and whether new patient starts continue to accelerate or normalize seasonally. Revenue guidance for coming quarters will indicate whether the company expects sustained growth or whether the September spike represents a temporary phenomenon. The progression of pipeline programs, particularly the adult SR-aGvHD trial and the inflammatory bowel disease program, will inform the long-term addressable market. Management’s comments about manufacturing expansion warrant attention, as capacity constraints could either accelerate growth or limit revenue opportunity.
Our exclusive top 5 stock picks
Five high conviction stocks that didn't make the public list. Backed by institutional research. Subscribe for free access.
Thanks for subscribing, please check your email to confirm your subscription to instantly access your report.
The announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Mesoblast Limited (ASX: MSB)
Mesoblast Limited is a biotechnology company headquartered in Melbourne, Australia, specializing in the development of allogeneic cellular medicines derived from adult stem cells. The company focuses on treating severe and life-threatening inflammatory conditions, with a pipeline spanning cardiovascular diseases, spine orthopedic disorders, and immune-mediated conditions. It is a world leader in the development of off-the-shelf cellular medicine therapies for these therapeutic areas.
If you would like to discuss this announcement, request a callback or call us on 1300 889 603.